Oral Regimens for AML Make Strides

According to two phase I/II trials, ASCERTAIN-V and SAVE, the all-oral regimen of decitabine-cedazuridine and venetoclax, with revumenib added in the latter study, could be an effective option for patients with acute myeloid leukemia who would otherwise receive intravenous or subcutaneous chemotherapy.

Publication Details

Journal
Cancer Discovery
Published
2026-06-27
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0073
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Oral Regimens for AML Make Strides

Cancer Discovery
Acute Myeloid Leukemia Research
article

Oral Regimens for AML Make Strides

article en

Abstract

According to two phase I/II trials, ASCERTAIN-V and SAVE, the all-oral regimen of decitabine-cedazuridine and venetoclax, with revumenib added in the latter study, could be an effective option for patients with acute myeloid leukemia who would otherwise receive intravenous or subcutaneous chemotherapy.

Cancer Discovery
Good health and well-being
Openalex Percentile: Top 7%
Acute Myeloid Leukemia Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.